Tango Therapeutics, Inc. (TNGX) Misses Q3 EPS by 7c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.14), $0.07 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $53.81 million versus the consensus estimate of $53.8 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• BW LPG Limited (BWLP) Reports Q1 EPS of $0.79
• Citi cuts FinVolution rating to Neutral, lowers target to $4.10
• PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit